OncoTherapy Science AI Stock Analysis
Want to see JP:4564 full AI Analyst Report?
OncoTherapy Science (4564) AI Stock Analysis
OncoTherapy Science
(TSE/TYO:4564)
The overall score is very low, driven primarily by weak technical momentum and a lack of profitability. The stock is in a clear downtrend with all technical indicators pointing to continued weakness. The company's negative earnings and cash flow present significant fundamental risks. The primary mitigating factor is a pristine, debt-free balance sheet, which provides a financial cushion but is not enough to offset the near-term operational and market headwinds.
OncoTherapy Science (4564) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 6.53B
- Dividend Yield
- ―
- Average Volume (3M)
- 188.56M
- Price to Earnings (P/E)
- -7.0
- Beta (1Y)
- 1.04
- Revenue Growth
- -25.56%
- EPS Growth
- 17.01%
- Country
- Japan
- Employees
- 46
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
OncoTherapy Science Business Overview & Revenue Model
Company Description
OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound th...
OncoTherapy Science Financial Statement Overview
Summary
Financial performance is mixed. The balance sheet is a major strength with no debt and a 91% equity-to-assets ratio, providing a solid runway. However, the income statement and cash flow are weak, marked by declining revenue, persistent net losses, and significant negative free cash flow, which are typical but high-risk for a clinical-stage biotech.
Income Statement
22NegativeBalance Sheet
85Very PositiveCash Flow
25Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 749.75M | 808.53M | 750.05M | 610.12M | 1.13B | 332.48M |
| Gross Profit | -12.76M | 13.96M | -12.76M | -177.72M | 41.69M | 19.54M |
| EBITDA | -126.67M | -810.38M | -14.92M | -165.50M | -1.10B | -1.59B |
| Net Income | -815.05M | -910.64M | -815.28M | -1.29B | -1.12B | -1.56B |
Balance Sheet | ||||||
| Total Assets | 1.16B | 2.36B | 1.16B | 867.27M | 1.51B | 3.37B |
| Cash, Cash Equivalents and Short-Term Investments | 833.88M | 2.09B | 833.88M | 527.66M | 1.12B | 2.90B |
| Total Debt | 51.07M | 0 | 51.07M | 106.85M | 0 | 0 |
| Total Liabilities | 426.09M | 217.37M | 426.09M | 513.61M | 656.27M | 291.28M |
| Stockholders Equity | 729.11M | 2.14B | 729.11M | 353.67M | 855.17M | 3.08B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -984.97M | -815.30M | -1.23B | -800.29M | -1.81B |
| Operating Cash Flow | 0 | -922.75M | -815.02M | -1.23B | -794.90M | -1.76B |
| Investing Cash Flow | 0 | -63.22M | -279.00K | -33.35M | -20.32M | -52.23M |
| Financing Cash Flow | 0 | 2.24B | 1.12B | 671.37M | 95.95M | 0 |
OncoTherapy Science Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4564, the sentiment is Negative. The current price of 16.00 is below the 20-day moving average (MA) of 17.25, below the 50-day MA of 19.54, and below the 200-day MA of 20.77, indicating a bearish trend. The MACD of -0.82 indicates Negative momentum. The RSI at 35.75 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4564.
OncoTherapy Science Peers Comparison
Overall Rating
JP:456566Neutral
JP:458855Neutral
JP:458748Neutral
JP:457943Neutral
JP:457141Neutral- JP:456441Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4565 | 66Neutral | JPY 167.91B | -30.31 | -8.51% | ― | 23.72% | 12.48% |
| JP:4588 | 55Neutral | JPY 248.42B | -152.49 | ― | ― | 1748.97% | 35.11% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:4587 | 48Neutral | JPY 138.26B | -47.42 | -5.85% | ― | 14.25% | 50.07% |
| JP:4579 | 43Neutral | JPY 16.82B | 72.18 | ― | ― | 31.84% | ― |
| JP:4571 | 41Neutral | JPY 6.10B | -4.98 | -33.61% | ― | 48.92% | -46.91% |
| JP:4564 | 41Neutral | JPY 6.53B | -6.96 | -42.81% | ― | -25.56% | 17.01% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4564 | OncoTherapy Science, Inc. | 16.00 | -7.00 | -30.43% | |
| JP:4587 | Peptidream | 1065.00 | -518.50 | -32.74% | |
| JP:4565 | Sosei Group Corporation | 1813.00 | 954.00 | 111.06% | |
| JP:4571 | NanoCarrier Co., Ltd. | 67.00 | -83.00 | -55.33% | |
| JP:4579 | RaQualia Pharma Inc. | 646.00 | 105.00 | 19.41% | |
| JP:4588 | Oncolys BioPharma, Inc. | 8410.00 | 7342.00 | 687.45% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 11, 2026